SCHEMBL4797494

SCHEMBL4797494

Cc1ncc(Oc2ccc(N)cc2Cl)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 1/20 0.51
MPO P05164 1/20 0.46
TPO P07202 1/20 0.46
EPX P11678 1/20 0.46
LPO P22079 1/20 0.46
CYP3A4 P08684 2/20 0.43
KDM4E B2RXH2 3/20 0.42
PDE7A Q13946 2/20 0.42
POLB P06746 1/20 0.42
HTR2A P28223 1/20 0.40
SLC6A4 P31645 1/20 0.40
TSHR P16473 1/20 0.38
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
PNLIP P16233 1/20 0.36
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MAPT P10636 2/20 0.34
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL159190 0.84 MPO (0.51) GRM4MPOTPOEPXLPO
SCHEMBL4798392 0.83 ALDH1A1 (0.41) GRM4MPOTPOEPXLPO
SCHEMBL4799213 0.81 KDM4E (0.50) GRM4CYP3A4KDM4ETSHRMEN1
SCHEMBL4797487 0.81 GRM4 (0.46) GRM4MPOTPOEPXLPO
SCHEMBL2747551 0.80 PDE7A (0.44) GRM4MPOTPOEPXLPO
SCHEMBL4794749 0.78 GRM2 (0.42) GRM4MPOTPOEPXLPO
SCHEMBL5570028 0.78 MPO (0.51) GRM4MPOTPOEPXLPO
SCHEMBL5583563 0.78 TEAD4 (0.57) CYP3A4KDM4EPDE7APOLBHTR2A
SCHEMBL10647827 0.78 MAPT (0.39) GRM4MPOTPOEPXLPO
SCHEMBL2415575 0.77 PDE7A (0.42) GRM4MPOTPOEPXLPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7332493-B2 Substituted bicyclic derivatives for the treatment of abnormal cell growth OSI PHARMACEUTICALS (US) 2008-02-19 US claimed
US-20050159435-A1 Substituted bicyclic derivatives for the treatment of abnormal cell growth PFIZER INC 2005-07-21 US claimed
US-6890924-B2 Substituted bicyclic derivatives for the treatment of abnormal cell growth PFIZER INC (US) 2005-05-10 US claimed
EP-1292591-B1 SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PROD INC (US) 2005-02-02 EP claimed
US-6890924-B2 Substituted bicyclic derivatives for the treatment of abnormal cell growth PFIZER INC (US) 2005-05-10 US disclosed
EP-1292591-B1 SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PROD INC (US) 2005-02-02 EP disclosed
US-20020169165-A1 Substituted bicyclic derivatives for the treatment of abnormal cell growth PFIZER PRODUCTS INC. 2002-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169165-A1 Substituted bicyclic derivatives for the treatment of abnormal cell growth CCNA1, CCNT1, CCNB1 GRM4 3324/4885MPO 4395/4885TPO 4817/4885
US-20050159435-A1 Substituted bicyclic derivatives for the treatment of abnormal cell growth CCNA1, CCNT1, CCNB1 GRM4 4041/4885MPO 4330/4885TPO 4764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.